特应性皮炎患者停用度普利尤单抗换用曲罗芦单抗或JAK抑制剂后结膜炎的演变(RESO-ADOC研究)
这项多中心回顾性队列研究纳入因度普利尤单抗相关结膜炎而停药并换用曲罗芦单抗或Janus激酶抑制剂的特应性皮炎患者。多因素分析显示,结膜炎病程、个人哮喘史以及换用JAK抑制剂与结膜炎完全缓解独立相关,提示对严重病例可考虑快速换用JAK抑制剂。
要点
- 度普利尤单抗相关结膜炎在真实世界中较临床试验更常见。
- 结膜炎病程、哮喘史和换用JAK抑制剂与结膜炎完全缓解独立相关。
- 对严重度普利尤单抗相关结膜炎,可考虑快速换用JAK抑制剂。
核心结论
- 度普利尤单抗相关严重结膜炎在真实世界中较关键试验更常见,对严重病例可考虑快速换用其他分子尤其是JAK抑制剂。
研究设计与样本
- 多中心回顾性队列研究,纳入所有因度普利尤单抗相关结膜炎停药并换用曲罗芦单抗或JAK抑制剂的AD患者。
- 在纳入访视(停用度普利尤单抗并启用新治疗)、访视2(纳入后3-6个月)和访视3(末次就诊)分析患者、AD及结膜炎数据。
主要发现
- 多因素分析显示,访视2和/或访视3时结膜炎完全缓解的唯一相关因素为结膜炎病程(OR 8.98,95%CI 1.47-55,p=0.018)。
- 个人哮喘史与结膜炎完全缓解相关(OR 10.66,95%CI 1.82-62.63,p=0.009)。
- 从度普利尤单抗换用JAK抑制剂与结膜炎完全缓解相关(OR 17.11,95%CI 2.94-99.66,p=0.002)。
临床怎么用
- 对度普利尤单抗相关结膜炎导致停药的患者,可考虑快速换用曲罗芦单抗或JAK抑制剂。
- 换用JAK抑制剂与结膜炎完全缓解相关,尤其可考虑用于有哮喘史或结膜炎病程较长的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials and real-life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some cases conjunctivitis will appear or increase after dupilumab initiation, which can lead to dupilumab discontinuation. OBJECTIVES: (1) To describe the characteristics of patients developing conjunctivitis requiring discontinuation of dupilumab; and (2) to analyse the factors associated with a complete conjunctivitis improvement after dupilumab discontinuation and a switch to tralokinumab or Janus kinase inhibitors. METHODS: This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed conjunctivitis leading to dupilumab discontinuation and switching to tralokinumab or Janus kinase inhibitors in daily practice. Data on patients, their AD and conjunctivitis were analysed at the inclusion visit (corresponding to discontinuation of dupilumab and the institution of new AD treatment), at visit 2 (3-6 months after inclusion) and at visit 3 (corresponding to the last medical visit). RESULTS: After multivariate analysis, the only factors associated with a complete resolution of dupilumab-associated conjunctivitis at visit 2 and/or visit 3 were conjunctivitis duration (OR 8.98, 95% CI 1.47-55) (p = 0.018), personal history of asthma (OR 10.66, 95% CI 1.82-62.63) (p = 0.009) and switching from dupilumab to Janus kinase inhibitors (OR 17.11, 95% CI 2.94-99.66) (p = 0.002). CONCLUSIONS: Although uncommon, severe dupilumab-associated conjunctivitis is more frequent in daily life compared to its incidence in the dupilumab pivotal trials. In these cases, our study suggests that a rapid switch to another molecule, particularly a Janus kinase inhibitor, should be considered.
引用
- Reguiai Z, Becherel PA, Perrot JL, et al. Evolution of dupilumab-associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO-ADOC study). J Eur Acad Dermatol Venereol. 2024. PMID: 39015045. doi:10.1111/jdv.20233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。